Table 2.
HRs and CIs for PFS for the multivariate Cox PH model with imaging metrics and the multivariate Cox PH model with clinical variables only (training set)
| PFS | OS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value |
C-Index test set |
AUC 2-years test set |
HR | 95% CI | P-value | C-Index test set | AUC 2-years test set | |
| Cox PH model with imaging metrics | ||||||||||
| Hemoglobin < LLN | 1.22 | 0.94–1.58 | .13 | 1.37 | 0.99–1.89 | .06 | ||||
| ECOG PS > 1 | 1.26 | 0.89–1.78 | .19 | 1.29 | 0.84–1.96 | .24 | ||||
| Ann Arbor stage IV | 1.41 | 1.10–1.82 | .007 | 1.49 | 1.08–2.04 | .01 | ||||
| aTMTV > Q3 | 1.31 | 0.98–1.74 | .06 | 0.63 | 0.59 | 1.18 | 0.83–1.67 | .35 | 0.62 | 0.61 |
| Number of lesions > 4 (median) | 1.62 | 1.23–2.71 | .0006 | 1.91 | 1.34–2.71 | .0003 | ||||
| Liver involvement | 1.16 | 0.82–1.64 | .40 | 1.03 | 0.68–1.58 | .88 | ||||
| LDH elevated | 1.12 | 0.86–1.46 | .39 | 1.30 | 0.93–1.82 | .12 | ||||
| Cox PH model with clinical variables only | ||||||||||
| Hemoglobin < LLN | 1.40 | 1.09–1.80 | .01 | 1.57 | 1.14–2.15 | .005 | ||||
| ECOG PS > 1 | 1.40 | 0.99–1.96 | .05 | 0.59 | 0.57 | 1.39 | 0.92–2.10 | .11 | 0.59 | 0.57 |
| Ann Arbor stage IV | 1.61 | 1.26–2.05 | .0001 | 1.68 | 1.24–2.28 | .0009 | ||||
| LDH elevated | 1.30 | 1.01–1.68 | .04 | 1.51 | 1.09–2.09 | .01 | ||||
CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HR Hazard ratio, LDH Lactate dehydrogenase, LLN Lower limit of normal, OS Overall survival, PFS Progression-free survival, PH Proportional hazard, Q3 Third quartile, TMTV Total metabolic tumor volume